Targeting these pathways, including ALDH1, NRF2, and TGFβ signaling, holds promise for overcoming chemoresistance and improving therapeutic outcomes in HNSCC [18]. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.